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ABSTRACT
Objective Conscious sedation is widely used in
endoscopic practice but is not without risk. We
aimed to determine the frequency of sedation
complications requiring reversal, and to identify
potential patient and procedural risk factors.
Design A retrospective study of all
gastrointestinal endoscopic procedures
performed under conscious sedation, in a large
three-campus tertiary referral endoscopic centre,
between 12 October 2007 and 31 December
2012 (n=52 553). Flumazenil or naloxone
administration was used as a marker of sedation
complications requiring reversal. Reversal cases
were analysed for associations with sedation
dose, patient American Society of
Anesthesiologists (ASA) grade, age and type of
procedure undertaken.
Results In total, 149 sedation reversals occurred,
representing 0.28% of all sedated endoscopic
procedures carried out. Endoscopic Retrograde
Cholangiopancreatography (ERCP) and increasing
patient ASA grade were positively associated
with sedation reversal (p<0.05). Mean
midazolam dose was highest for ERCP (4.9
±2.9 mg) and lowest for flexible sigmoidoscopy
(1.7±0.6 mg; p<0.01). Mean opioid dose
(calculated as pethidine equivalent) was highest
for ERCP (62.9±38.7 mg) and lowest for
gastroscopy (6.9±13.5 mg; p<0.01). Maximum
doses of midazolam or opioid recommended by
the British Society of Gastroenterology were
exceeded in 7.4% and 14.1% of reversals,
respectively.
Conclusions ERCP procedures and higher
patient ASA grade were associated with an
increased risk of conscious sedation-related
complications requiring reversal. In these high-
risk groups, alternative sedation strategies should
be considered and tested. Prospective studies are
needed to further explore risk factors that may
help predict adverse sedation outcomes.
INTRODUCTION
While sedation plays an integral role in
endoscopic practice, it is not without
risk. Most gastrointestinal (GI) endo-
scopic procedures are performed under
‘conscious sedation’, a drug-induced
depression of consciousness during which
patients are able to maintain purposeful
responses to verbal or tactile stimulation,
and cardiorespiratory function remains
intact.1
Over the past decade, there has been a
significant increase in awareness of the
potential hazards of endoscopic sedation.
Synergistic action between benzodiaze-
pines and opioids further increases this
risk. In a nationwide study from the USA,
96.9% of all endoscopic procedures were
performed under conscious sedation.
Complications occurred in 1.4% of cases,
of which 0.9% were cardiorespiratory
events.2 Safe sedation guidelines produced
by the British Society of Gastroenterology
(BSG) and the American Society for
Gastrointestinal Endoscopy highlight the
need for accurate patient risk stratifica-
tion, close procedural monitoring and
minimisation of sedation doses.3 4
A UK National Confidential Enquiry
into Patient Outcome and Death (2004)
evaluated inpatient deaths occurring
within 30 days of therapeutic GI endo-
scopic procedures. In 14% of cases, the
sedation doses were judged to be inappro-
priate.5 Serious harm or death resulting
from midazolam or opioid overdose
during conscious sedation is now a UK
Department of Health ‘Never Event’
(2012–2013).6
Establishing risk factors to help predict
adverse responses to conscious sedation
may help reduce the incidence of
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sedation-related complications. In this study, we retro-
spectively analysed GI endoscopic procedures per-
formed under conscious sedation (midazolam
±opioid) over a 5-year period. Our objective was to
assess the frequency of sedation complications requir-
ing reversal, and to identify potential patient and pro-
cedure related risk factors.
METHODS
Study population
Imperial College Healthcare NHS Trust, London, UK,
comprises a large three-campus tertiary referral endo-
scopic centre, with an estimated catchment population
of 650 000.7 The three endoscopic units based at
Charing Cross, St Mary’s and Hammersmith hospi-
tals, undertake around 17 000 endoscopic procedures
per annum.7 We performed a retrospective analysis of
endoscopic procedures carried out in the Trust
between 12 October 2007 and 31 December 2012.
All endoscopic procedures performed under conscious
sedation (midazolam±opioid), excluding propofol
administration, were included in the study. We com-
pared our results with a previous two-site Trust audit
conducted by our group between 1 January 2000 and
31 December 2005 (unpublished data).
Endoscopic data collection
The Trust endoscopy reporting software and database
system ‘Scorpio’ (Ascribe, UK), was analysed to iden-
tify all sedation reversal events that occurred between
12 October 2007 and 31 December 2012. Flumazenil
or naloxone administration was used as a marker of
sedation complications requiring reversal treatment.
Only reversal events that occurred during or immedi-
ately after the procedure, in the endoscopy room,
were included in our study.
Patient and procedure related risk factors for sedation
reversals
The endoscopic records for all patients who received
sedation reversal drugs, flumazenil or naloxone,
during their endoscopic procedure were analysed to
identify patient age, the documented American
Society of Anesthesiologists (ASA) grade, type of pro-
cedure undertaken, type of sedation used and the
total doses of midazolam±opioids administered.
All opioid doses were converted to pethidine
equivalent doses to allow comparison. We note that
there are differences in the literature regarding opioid
conversion ratios and the published experience is
limited. We used the conversion ratio of 100 μg fen-
tanyl being approximately equivalent to 75 mg pethid-
ine based on their equivalent analgesic activity, and
1 mg alfentanil being approximately equivalent to
150 mg pethidine.8–11 Conversion calculations are
detailed in online supplementary appendix 1.
30 day mortality rate following endoscopic procedures
All cases where patients died within 30 days of their
endoscopic procedure were identified. Individual case
notes for these patients were obtained from medical
records to assess the rationale for the endoscopy, type
and doses of sedation used, documented reason for
sedation reversal, the patient’s medical history, ASA
grade, and whether the sedation used during the
endoscopic procedure may potentially have contribu-
ted to the mortality.
Statistical analysis
Results were expressed as mean±SD for continuous
variables and frequency (%) for categorical variables.
Statistical analysis was carried out using χ2 test and
the linear regression model. All tests were performed
using Origin (OriginLab Corporation, USA). In all
cases, the null hypothesis tested was that there was no
association between the variables, and a p value of
<0.05 was considered statistically significant.
RESULTS
A total of 73 989 endoscopic procedures were per-
formed across the three endoscopic units over the
study period. Conscious sedation (midazolam
±opioid) was used in 52 553 procedures. Flumazenil
or naloxone was required in 149 endoscopic cases,
representing 0.28% of all sedated endoscopic proce-
dures carried out. This was comparable with our pre-
vious audit, 2000–2005, with a sedation reversal rate
of 0.27%. No significant difference was noted in the
overall sedation reversal rate between the two study
periods (0.28% vs 0.27%; p>0.79).
Endoscopic Retrograde Cholangiopancreatography
(ERCP) was the procedure type most commonly asso-
ciated with sedation reversal, with a sedation reversal
rate of 1.0% (p<0.05) (figure 1A). This was followed
by enteroscopy (0.40% reversal rate), gastroscopy
(0.27%), colonoscopy (0.22%), flexible sigmoidos-
copy (0.21%) and endoscopic ultrasound (0.09%).
Patient demographics for sedation reversal events
are presented in table 1. There was a positive associ-
ation with sedation reversal and increasing patient
ASA grade (p<0.05) (figure 1B). No significant asso-
ciation was found between patient age (≤ or >70
years) and the frequency of sedation reversal events.
The mean dose of midazolam used in reversal
events was 3.0 mg (range 0.5–14 mg). The mean dose
of midazolam varied by procedure type and was
highest for ERCP (4.9±2.9 mg) and lowest for flex-
ible sigmoidoscopy (1.7±0.6 mg; p<0.01) (see online
supplementary appendix 2). Midazolam doses exceed-
ing 5 mg were administered in 7.4% of reversal cases
(11/149 procedures, nine of which were ERCP
procedures).
Opioids were used in 55.7% of reversal cases (83/
149 procedures) and included pethidine, fentanyl or
alfentanyl. All opioid doses were converted to a
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pethidine equivalent dose. The mean pethidine
equivalent dose of opioid used was 47.9 mg (range
12.5–150 mg). The mean dose of opioid varied
according to the procedure-type and was highest for
ERCP (62.9±38.7 mg) and lowest for gastroscopy
(6.9±13.5 mg; p<0.01) (see online supplementary
appendix 2). One enteroscopy procedure used a peth-
idine equivalent dose of 75 mg, however, given that
this was the only enteroscopy reversal to occur, we
have taken the highest statistically significant mean
dose of opioid to remain for ERCP. Pethidine
equivalent doses exceeding 50 mg were administered
in 25.3% of reversal cases where an opioid had been
used (21/83 procedures, 18 of which were ERCP pro-
cedures), representing 14.1% of the total number of
sedation reversal events.
No significant association was found between the
mean dose of midazolam or opioid used in sedation
reversal events and patient age (≤ or >70 years).
The main reasons for sedation reversal were:
hypoxia, hypotension, bradycardia, a reduced level of
responsiveness and risk of aspiration from food
Figure 1 (A) Sedation reversal and type of procedure. Bar graph showing the association between the percentage of sedation
reversal events and type of endoscopic procedure. (B) Sedation reversal rate and ASA grade. Bar graph showing the positive
association between the percentage of sedation reversal events and patient ASA grade. ASA grade: (1) fit; (2) mild systemic; (3)
severe systemic; (4) life-threatening systemic. ASA, American Society of Anesthesiologists; ERCP, endoscopic retrograde
cholangiopancreatography; EUS, endoscopic ultrasound.
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residue (table 2). In 56 procedures (37.6% of reversal
cases), the rationale for the use of reversal agents had
not been specified.
Ten patients died within 30 days of their endoscopic
procedure being carried out. These patients’ case
notes were obtained from the medical records depart-
ment (under the Data Protection Act 1998). Details of
the 10 cases are presented (table 3). Four patients
underwent upper GI endoscopies for percutaneous
endoscopic gastrostomy placement, three patients
required ERCPs for stent insertion, and three upper
GI endoscopies were performed for haematemesis or
melaena. Interestingly, on more detailed analysis, we
found that the ASA grades documented for five
patients had been underestimated. Overall, seven out
of the ten patients were deemed to be ASA Grade 3
(severe systemic illness) and three patients ASA Grade
4 (severe systemic illness with a constant threat to
life). Although these patients all experienced sedation-
related complications requiring reversal, on review,
the sedation did not appear to be a likely factor con-
tributing to mortality.
DISCUSSION
Conscious sedation remains the most commonly used
endoscopic sedation strategy; improving patient
comfort and overall endoscopist satisfaction.13 With
increasing numbers of endoscopic procedures per-
formed each year, patient safety is of vital importance.
Serious harm or death resulting from midazolam or
opioid overdose during conscious sedation is now a
UK Department of Heath ‘Never Event’.6 However,
data reporting endoscopic sedation-related complica-
tions varies widely, and few studies have explored the
risk factors behind these adverse events. In this study,
we focus on sedation-related complications significant
enough to necessitate sedation reversal.
To the best of our knowledge, only one previously
published study has specifically examined predictive
factors for reversal agent use in GI endoscopy,
however, this study from the USA was confined to
ERCP procedures only.14 Our study is the first to
examine sedation reversal events in detail across the
full spectrum of GI endoscopic procedure types. We
also believe it to be the largest retrospective study of
endoscopic sedation reversal events in Europe. Our
5-year analysis, across a three-campus tertiary referral
endoscopic centre, has revealed a subset of patients
and procedures that may carry an increased risk of
developing sedation-related complications requiring
reversal. Identifying such risk factors may enable more
accurate risk stratification prior to endoscopy and
allow consideration, where necessary, of alternative
sedation techniques.
First, our results suggest that patients with a higher
ASA grade may be more likely to incur sedation-
related complications requiring reversal. In support of
this, a review of 324 737 endoscopic procedures by
Sharma et al reported higher ASA grades to be a sig-
nificant independent risk factor for cardiorespiratory
unplanned events.2 Old age (>60 years) and inpatient
status were also identified as potential patient risk
factors for endoscopic cardiopulmonary complica-
tions.2 Since inpatients tend to be more unwell than
outpatients, ASA grade may be a potential confounder
for an inpatient association. Interestingly, in our study,
we did not find a significant association between the
frequency of sedation reversal events and patient age
(less than vs greater than 70 years). We hypothesise
that this may be due to more gradual increments of
sedation being used in elderly patients, although pro-
spective studies will be required to substantiate this.
Our data suggest that ERCP procedures may be asso-
ciated with a higher rate of sedation complications
requiring reversal compared with other endoscopic pro-
cedure types. Chawla et al reported the grade of diffi-
culty of cannulation in ERCPs as a variable significantly
associated with failure of gastroenterologist-directed
conscious sedation.15 Furthermore, we found that
ERCP procedures involved higher mean sedation doses.
Despite synergistic effects between benzodiazepines and
Table 1 Patient demographics in sedation-reversal events
Patient demographics
Number of patients
(% of total)
Age
≤70 79 (53.0)
>70 70 (47.0)
Sex
Male 66 (44.3)
Female 83 (56.7)
ASA grade
1 Fit 45 (30.2)
2 Mild systemic disease 53 (35.6)
3 Severe systemic disease 43 (28.9)
4 Severe systemic disease with a constant
Threat to life
6 (4.0)
Not specified 2 (1.3)
ASA, American Society of Anesthesiologists.12
Table 2 Documented rationale for sedation-reversal events
Indication for sedation reversal
Number of reversal events
(% of total)
Hypoxia 28 (18.8)
Hypotension 26 (17.4)
Bradycardia 1 (0.7)
Respiratory depression 2 (1.3)
Reduced responsiveness 24 (16.1)
Risk of aspiration 12 (8.1)
Procedure abandoned due to poor
bowel preparation
2 (1.3)
Patient discomfort/agitation 2 (1.3)
Drug induced ileus 1 (0.7)
Chest pain 1 (0.7)
Not specified 56 (37.6)
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opioids, higher doses of midazolam were frequently
coupled with higher doses of opioids in ERCP proce-
dures, providing a potential explanation for the
increased rate of sedation complications in this group.
More than 48 000 ERCP procedures are performed
in the UK each year.16 Due to their complex and
often prolonged nature, ERCP procedures tend to
require sedation for longer periods of time, leading to
higher total sedation doses compared with routine
upper or lower GI endoscopy. In view of this, a
number of studies have explored different sedation
combinations for these higher risk procedures.1 4 17 18
Propofol is a rapid-onset, short-acting anaesthetic
agent used to achieve deep sedation. Its use in endo-
scopic procedures in the UK remains limited, requir-
ing the presence of a trained anaesthetist due to an
increased risk of respiratory depression.19 Routine
use of propofol incurs greater staffing demands,
procedure time and costs and is, therefore, unrealis-
tic. However, increasingly, studies have shown that
with appropriate caution, propofol may be an
appropriate alternative sedation strategy for certain
endoscopic procedures, particularly in high-risk
groups.1 17 18 20
A systematic review of studies comparing conscious
sedation with deep sedation (propofol) in ERCP pro-
cedures found no significant difference in sedation-
related complications between patient groups.
Moreover, propofol administration was associated
with faster patient recovery and higher patient satis-
faction.18 Similarly, a randomised controlled trial
comparing conscious sedation with propofol in high-
risk patient groups (patients over the age of 80 years,
with an ASA grade of 3 or above) found similar pro-
cedure tolerability in both groups, while propofol was
associated with shorter recovery times and fewer
oxygen desaturation events.20 This suggests that in
select patients, propofol administration may be a safe
and feasible option when administered by trained
personnel.
The overall frequency of sedation complications
necessitating reversal in our study was 0.28%.
Table 3 Cases of mortality within 30 days of the endoscopic procedure
Procedure
type
Patient
age
(years)
Indication for
procedure
ASA grade
documented
Sedation
used Reason for reversal
Factors contributing to
mortality
ERCP 80 Obstructive jaundice Severe systemic Midazolam
2 mg, Fentanyl
75 μg
Persistent hypoxia Intracranial event, sepsis secondary
to pneumonia, acute renal failure
OGD 81 Melaena Fit
(*Severe systemic)
Midazolam
1 mg
Hypotension Recurrent GI bleed with no bleeding
source identifiable. Pulmonary
oedema, aspiration pneumonia,
cellulitis
ERCP 59 Stent insertion
(pancreatic cancer with
gastric outlet
obstruction)
Severe systemic
(*Life-threatening)
Midazolam
3 mg, Fentanyl
50 μg
Deep sedation and food
residue in stomach (risk of
aspiration in recovery)
Metastatic pancreatic
adenocarcinoma
OGD 85 PEG placement (unsafe
swallow)
Severe systemic Midazolam
2 mg
Hypoxia, reduced
responsiveness
Aspiration pneumonia, acute
mesenteric ischaemia likely embolic
in origin secondary to AF
ERCP 45 CBD stricture, stent
insertion
Severe systemic
(*Life-threatening)
Midazolam
4 mg, Fentanyl
50 μg
Low respiratory rate Advanced metastatic breast
carcinoma
OGD 66 PEG placement (unsafe
swallow)
Mild systemic
(*Severe systemic)
Midazolam
2 mg, Pethidine
50 mg
Reduced responsiveness,
not rousable
postprocedure
Pneumonia, poor compliance with
treatment secondary to dementia
OGD 76 Haematemesis Mild systemic
(*Life-threatening)
Midazolam
4 mg
Food residue in stomach
(aspiration risk)
Advanced metastatic oesophageal
cancer, persisting GI bleed (patient
refused further intervention)
OGD 56 PEG placement Severe systemic Pethidine
50 mg
Reduced responsiveness
postprocedure
HIV-associated progressive multifocal
leucoencephalopathy
OGD 86 Melaena Severe systemic Midazolam
2.5 mg
Hypoxia GI bleed with no bleeding source
identifiable, pulmonary oedema,
worsening acute on chronic renal
failure
OGD 90 PEG placement Severe systemic Midazolam
1 mg
Hypoxia Hospital-acquired pneumonia,
Clostridium difficile infection, GI
bleeding, congestive cardiac failure
*Pre-endoscopy patient ASA grade deemed to be different after review of individual patient medical case notes.
ASA, American Society of Anesthesiologists; AF, atrial fibrillation; CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography;
GI, gastrointestinal; OGD, oesophago-gastro-duodenoscopy; PEG, percutaneous endoscopic gastrostomy.
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By comparison, a study of 21 011 endoscopic proce-
dures by Arrowsmith et al reported serious cardiopul-
monary complications in 0.54% of procedures using
midazolam or diazepam.21 Sharma et al2 reported a
complication rate of around 1.4% of endoscopic pro-
cedures performed under conscious sedation. Of note,
our study only included endoscopic cases where sed-
ation complications necessitated reversal, therefore,
the total frequency of sedation-related complications,
including those not significant enough to require
reversal, is likely to be higher than 0.28%.
The majority of sedation complications encountered
in our study were cardiorespiratory events. In over a
third of reversal cases, the specific nature of the compli-
cations necessitating reversal had not been documented
on the endoscopy report. This information is valuable
to help with future patient risk factor stratification and
decisions regarding sedation strategies, therefore, more
detailed documentation of sedation reversal events on
endoscopic records should be provided.
The range of sedation doses used in our study was
broad, with a midazolam dose range between 0.5 and
14 mg, and a pethidine equivalent dose range between
12.5 and 150 mg. The majority of endoscopic proce-
dures requiring sedation reversal did not, however,
involve excessively high sedation doses. Indeed, the
mean dose of midazolam used in reversal events was
3.0 mg and the mean opioid dose (pethidine equiva-
lent) was 47.9 mg, both within the maximum recom-
mended doses specified by BSG safe sedation
guidelines (ie, midazolam 5 mg, pethidine 50 mg).3
Overall, higher doses of midazolam or opioid than
those recommended by the BSG were used in a total
of 7.4% and 14.1% of all reversal cases retrospect-
ively; this predominantly occurring during ERCP pro-
cedures. Arrowsmith et al21 found that in all cases of
cardiopulmonary complications, no patients had
received more than 10 mg midazolam. These observa-
tions suggest that sedation-related complications may
still occur at relatively lower doses of sedation and
may be influenced by multiple factors including ASA
grade and a patient’s inherent sensitivity to sedation,
rather than by high sedation doses alone.
Our study is a retrospective analysis and is, there-
fore, limited by reliance on accurate documentation
by endoscopists, particularly regarding the sedation
doses given, the use of reversal agents and accurate
patient ASA grade classifications. The ASA grades for
five (out of 10) patients who died within 30 days of
their procedure, had been underestimated, suggesting
that ASA grades documented on endoscopy reports
may not always have been accurately assessed prior to
endoscopy. Only reversal agents administered in the
endoscopy room were recorded in our study, there-
fore, any reversal events occurring postprocedure, in
recovery areas, were not included.
Using endoscopy records retrospectively, the
required data was not available to ascertain whether
sedation increments or boluses had been given. We
hypothesise that in some cases where complications
occurred with low sedation doses, boluses of sedation
may have been given rather than increments titrated
to effect. We plan on investigating this further with
prospective studies, comparing reversal rates in endo-
scopic procedures where sedation boluses versus incre-
ments are given.
Interestingly, no significant difference occurred in
the frequency of sedation reversal events in our
current study (2007–2012) compared with our pre-
vious audit (2000–2005). This is likely to be due, at
least in part, to suboptimal adherence to sedation
guidelines. Several published studies demonstrate
that, in general, adherence to guidelines in clinical
practice remains inadequate. A systematic review by
McGlynn et al22 identified that patients in the USA
received 54.9% of guideline-recommended care.
Furthermore, a systematic review by Ebben et al23
showed a wide variation of adherence to clinical
guidelines, between 7.8% and 95% in a prehospital
setting, and 0% and 98% in the emergency depart-
ment. Responsible factors identified included
lack of evidence or applicability, lack of knowledge
of the recommendations and organisational
constraints.22 23
Despite the introduction of sedation guidelines
emphasising patient stratification, we have shown that
errors are persisting in assigning accurate ASA grades
to patients prior to endoscopy. This may influence the
degree of caution endoscopists apply to sedation.
Furthermore, in view of resources restricting the use
of deep sedation, we suspect that ERCP sedation prac-
tices have not significantly changed between the two
study periods in our Trust. We, therefore, propose
that more stringent preprocedural patient stratifica-
tion, as well as more frequent application of
anaesthetist-supported deep sedation for ERCP proce-
dures, may help to reduce our stationary sedation
reversal rates. Additional tailored interventions are
needed to improve awareness and adherence to sed-
ation guidelines in our Trust.
In conclusion, to the best of our knowledge, this
study is the first to examine sedation reversal events in
detail across a full spectrum of GI endoscopic proced-
ure types. Our data suggest that ERCP procedures and
higher patient ASA grade may help predict an
increased risk of conscious sedation-related complica-
tions requiring reversal. In these high-risk groups,
alternative sedation strategies should be considered.
Well-powered prospective studies are needed to
compare the use of propofol to conscious sedation in
ERCP procedures and patients with higher ASA
grades to assess for an impact on the frequency of sed-
ation reversal events. Prospective studies are urgently
awaited to explore and further determine potential
risk factors in order to accurately predict adverse sed-
ation outcomes.
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Significance of the study
What is already known on this topic?
▸ Endoscopic sedation-related complications remain a
major concern.
▸ Serious harm or death resulting from midazolam or
opioid overdose during conscious sedation is a UK
Department of Health ‘Never Event’.
▸ Safe sedation guidelines encourage patient risk strati-
fication, close procedural monitoring and minimisa-
tion of sedation doses.
What this study adds?
▸ ERCP procedures and higher patient ASA grade
appear to be associated with higher rates of con-
scious sedation-related complications requiring
reversal.
▸ ERCP procedures appear to be associated with higher
doses of both midazolam and opioids in sedation
reversal events.
How might it impact on clinical practice in the
foreseeable future?
▸ In prolonged therapeutic ERCP procedures and high
risk patient groups, alternative sedation strategies,
including the use of propofol, may help to reduce the
frequency of adverse sedation events.
▸ Prospective studies are needed to further establish
variables that may help predict adverse responses to
conscious sedation in endoscopy.
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